Yoshinobu Onuma mainly focuses on Stent, Surgery, Internal medicine, Cardiology and Coronary artery disease. His work deals with themes such as Clinical endpoint, Everolimus and Mace, which intersect with Stent. Internal medicine is represented through his Percutaneous coronary intervention and Myocardial infarction research.
His study looks at the relationship between Myocardial infarction and topics such as Hazard ratio, which overlap with EuroSCORE. Yoshinobu Onuma combines subjects such as Percutaneous and Prospective cohort study with his study of Cardiology. As a member of one scientific family, he mostly works in the field of Coronary artery disease, focusing on Fractional flow reserve and, on occasion, Computed tomography angiography, Cardiothoracic surgery, Hyperaemia and Receiver operating characteristic.
Yoshinobu Onuma mainly investigates Internal medicine, Cardiology, Percutaneous coronary intervention, Surgery and Stent. His Internal medicine study focuses mostly on Myocardial infarction, Coronary artery disease, Revascularization, Drug-eluting stent and Hazard ratio. His work on Angioplasty, Artery and Regurgitation is typically connected to In patient as part of general Cardiology study, connecting several disciplines of science.
His work is dedicated to discovering how Percutaneous coronary intervention, Conventional PCI are connected with Percutaneous and other disciplines. His studies deal with areas such as Bioresorbable vascular scaffold, Mace, Everolimus and Bioresorbable scaffold as well as Surgery. His Stent research is within the category of Radiology.
His main research concerns Percutaneous coronary intervention, Internal medicine, Conventional PCI, Cardiology and Myocardial infarction. His work carried out in the field of Percutaneous coronary intervention brings together such families of science as Stent, Clinical endpoint, Randomized controlled trial, Confidence interval and Stroke. As a part of the same scientific study, he usually deals with the Stent, concentrating on Intravascular ultrasound and frequently concerns with Lesion.
Yoshinobu Onuma studies Internal medicine, focusing on Hazard ratio in particular. His Conventional PCI research incorporates elements of Coronary artery disease, Ticagrelor, Acute coronary syndrome and Revascularization. His Cardiology study integrates concerns from other disciplines, such as Subgroup analysis and Cohort.
The scientist’s investigation covers issues in Percutaneous coronary intervention, Conventional PCI, Randomized controlled trial, Internal medicine and Myocardial infarction. His Percutaneous coronary intervention research is multidisciplinary, incorporating perspectives in Stent, Stroke, Clinical endpoint, Angiography and Cardiac surgery. His Stent research includes themes of Intravascular ultrasound, Thrombosis and Nuclear medicine.
His research investigates the connection with Conventional PCI and areas like Drug-eluting stent which intersect with concerns in Standard of care, Biomedical engineering, Stent design and Bioresorbable scaffold. His studies examine the connections between Randomized controlled trial and genetics, as well as such issues in Regimen, with regards to Stent implantation, Concomitant, Therapy duration and Interventional cardiology. As part of one scientific family, he deals mainly with the area of Internal medicine, narrowing it down to issues related to the Cardiology, and often Confidence interval.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods
Patrick W Serruys;John A Ormiston;Yoshinobu Onuma;Evelyn Regar.
The Lancet (2009)
Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II
Vasim Farooq;David Van Klaveren;Ewout W. Steyerberg;Emanuele Meliga.
The Lancet (2013)
A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial
John A Ormiston;Patrick W Serruys;Evelyn Regar;Dariusz Dudek.
The Lancet (2008)
Evaluation of the Second Generation of a Bioresorbable Everolimus-Eluting Vascular Scaffold for the Treatment of De Novo Coronary Artery Stenosis: 12-Month Clinical and Imaging Outcomes
Patrick W. Serruys;Yoshinobu Onuma;Dariusz Dudek;Pieter C. Smits.
Journal of the American College of Cardiology (2010)
A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial
Patrick W Serruys;Bernard Chevalier;Dariusz Dudek;Angel Cequier.
The Lancet (2015)
Assessment of the SYNTAX score in the Syntax study
Patrick W. Serruys;Yoshinobu Onuma;Scot Garg;Giovanna Sarno.
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial
Pascal Vranckx;Marco Valgimigli;Peter Jüni;Christian Hamm.
The Lancet (2018)
Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial
Patrick W Serruys;Bernard Chevalier;Yohei Sotomi;Angel Cequier.
The Lancet (2016)
Early and persistent intraventricular conduction abnormalities and requirements for pacemaking after percutaneous replacement of the aortic valve.
Nicolo Piazza;Yoshinobu Onuma;Emile Jesserun;Peter Paul Kint.
Jacc-cardiovascular Interventions (2008)
Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study.
Lorenz Räber;Michael Magro;Giulio G. Stefanini;Bindu Kalesan.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: